Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
November 22, 2022 07:00 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates
November 11, 2022 07:00 ET
|
Century Therapeutics, Inc.
- Preclinical data support next generation platform for iPSC-derived NK cells with multiple gene edits to improve persistence and anti-tumor efficacy - - iPSC-derived CAR gamma delta T cells shown...
Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 10, 2022 07:30 ET
|
Century Therapeutics, Inc.
- Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell malignancies expected to begin imminently - - Ended third quarter 2022 with cash, cash equivalents, and...
Century Therapeutics to Host Virtual Research and Development Day on November 11, 2022
November 02, 2022 07:05 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
Century Therapeutics to Present at the SITC 37th Annual Meeting
October 05, 2022 16:05 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors
October 03, 2022 07:00 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
Century Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference
September 26, 2022 07:00 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
Century Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 07:00 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to Overcome Three Major Pathways of Host vs Graft Rejection
August 25, 2022 07:30 ET
|
Century Therapeutics, Inc.
– Investigational New Drug Application for CNTY-101, a CAR-iNK product candidate targeting CD19 for B-cell malignancies, cleared by FDA – – First cell product candidate engineered with six precision...
Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
August 11, 2022 07:30 ET
|
Century Therapeutics, Inc.
- Following the recent submission of the IND application for CNTY-101 and pending FDA clearance, the Phase 1 ELiPSE-1 trial in relapsed/refractory lymphoma is on track to commence in the second half...